SG Americas Securities LLC Purchases 5,645 Shares of Humacyte, Inc. (NASDAQ:HUMA)

SG Americas Securities LLC increased its stake in Humacyte, Inc. (NASDAQ:HUMA) by 52.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 16,340 shares of the company’s stock after buying an additional 5,645 shares during the period. SG Americas Securities LLC’s holdings in Humacyte were worth $46,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Humacyte by 13.2% in the second quarter. BlackRock Inc. now owns 4,304,505 shares of the company’s stock worth $12,311,000 after buying an additional 501,265 shares during the last quarter. Vanguard Group Inc. raised its stake in Humacyte by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 3,018,967 shares of the company’s stock valued at $8,846,000 after acquiring an additional 50,331 shares during the period. Geode Capital Management LLC lifted its holdings in Humacyte by 4.6% during the second quarter. Geode Capital Management LLC now owns 1,101,967 shares of the company’s stock valued at $3,152,000 after purchasing an additional 48,034 shares during the last quarter. State Street Corp boosted its position in Humacyte by 57.3% during the second quarter. State Street Corp now owns 1,039,280 shares of the company’s stock worth $2,972,000 after purchasing an additional 378,485 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Humacyte by 3.7% in the third quarter. Northern Trust Corp now owns 518,586 shares of the company’s stock worth $1,519,000 after purchasing an additional 18,578 shares in the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Price Performance

Humacyte stock opened at $3.70 on Monday. The stock has a market cap of $440.60 million, a price-to-earnings ratio of -3.46 and a beta of 1.46. The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of 1.20. The business has a 50-day simple moving average of $3.53 and a 200 day simple moving average of $2.98. Humacyte, Inc. has a 52 week low of $1.96 and a 52 week high of $5.60.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same period in the previous year, the business posted ($0.21) EPS. On average, research analysts forecast that Humacyte, Inc. will post -0.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HUMA. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Humacyte in a research note on Monday, April 1st. Piper Sandler reaffirmed a “neutral” rating and issued a $4.00 price target on shares of Humacyte in a report on Tuesday, March 26th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research report on Monday, March 25th.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.